These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 33166580)

  • 1. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
    Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
    Floege J; Rovin BH
    Kidney Int; 2021 Apr; 99(4):811-813. PubMed ID: 33745547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
    Rojas-Rivera J; Fervenza FC; Ortiz A
    Drugs; 2022 Feb; 82(2):109-132. PubMed ID: 34932208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
    Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
    Medicine (Baltimore); 2021 Jul; 100(28):e26628. PubMed ID: 34260552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial.
    Xu J; Zhang W; Xu Y; Shen P; Ren H; Wang W; Li X; Pan X; Chen N
    Contrib Nephrol; 2013; 181():152-62. PubMed ID: 23689577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial.
    Duan Y; Bai Y; Guo W; Wang L; Dai W; Guo W; Huang H; Liu W; Diao Z
    Nephrol Dial Transplant; 2023 Dec; 39(1):95-102. PubMed ID: 37437905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy.
    Wang Y; Ma X; Yang X; Bai S; Zang X; Liao L; Wang Y; Lv Z; Zhang T; Zhuang S; Liu N
    Ren Fail; 2024 Dec; 46(2):2409353. PubMed ID: 39351796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
    Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P;
    J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study.
    Chen S; Ren S; Wang AY; Tran H; Li Z; Cheng X; Liu M; Li G; Wang L; Hong D
    Trials; 2020 Feb; 21(1):219. PubMed ID: 32093742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.
    Rojas-Rivera J; Fernández-Juárez G; Ortiz A; Hofstra J; Gesualdo L; Tesar V; Wetzels J; Segarra A; Egido J; Praga M
    Clin Kidney J; 2015 Oct; 8(5):503-10. PubMed ID: 26413273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
    Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
    BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
    Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
    Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
    Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
    BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
    Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
    Medicine (Baltimore); 2021 Dec; 100(51):e28225. PubMed ID: 34941086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
    Chen M; Zhang X; Xiong Y; Xu G
    Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.